Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: A case report

被引:32
|
作者
Chen, JL
Spinowitz, N
Karwa, M
机构
[1] Univ Hosp, Albert Einstein Coll Med, Dept Pharm, Bronx, NY 10467 USA
[2] Univ Hosp, Albert Einstein Coll Med, Montefiore Med Ctr,Dept Med, Div Internal Med, Bronx, NY 10467 USA
[3] Univ Hosp, Albert Einstein Coll Med, Montefiore Med Ctr,Dept Med, Div Critical Care Med, Bronx, NY 10467 USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 07期
关键词
D O I
10.1592/phco.23.7.940.32725
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A 44-year-old woman with a history of major depression and obsessive-compulsive disorder was prescribed mirtazapine. She came to the emergency department approximately 2 months after starting therapy; severe hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis were diagnosed. Although these adverse effects have been reported in early clinical trials, we found only three published cases of subclinical pancreatitis possibly associated with mirtazapine therapy We suspect that mirtazapine-associated hypertriglyceridemia had contributed to the development of acute pancreatitis and diabetic ketoacidosis in our patient. All these problems resolved with supportive care and discontinuation of mirtazapine. Her serum amylase, lipase, and lipid levels were normal 2 months after the acute event occurred. Health care providers should be aware of these possible adverse effects. Serum glucose and triglyceride levels should be measured at baseline and monitored regularly thereafter in all patients receiving mirtazapine therapy.
引用
收藏
页码:940 / 944
页数:5
相关论文
共 50 条